DennisJosephSlamonMD

Breast Cancer, Hematologic Oncology

UCLA School of Medicine

Dr. Slamon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Medical 530 420 120 Plz
# 365
Los Angeles, CA 90095
Phone+1 310-825-5193

Fax+1 310-267-2301

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
University of ChicagoResidency, Internal Medicine, 1975 - 1979
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975

PubMed

Lectures

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorâ€“positive (HR+), human epidermal growth factor recept...
2019 ASCO Annual Meeting - 6/1/2019
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
University of California, Costa Mesa, California - 5/17/2013
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€) advanced breast cancer (ABC): Results from MO...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

FDA Approval After Promising Results for Reducing Breast Cancer in Clinical TrialsOctober 21st, 2024
UCD Ulysses Medal for US Oncologist Dr Dennis Slamon Who Developed Breast Cancer Drug HerceptinSeptember 27th, 2024
FDA Approves Novartis’ Kisqali to Reduce Risk of Recurrence in Women with Breast CancerSeptember 25th, 2024
Join now to see all

Cru - Clinical Research Unit Shared ResourceNational Cancer Institute2009–2012
The Transcription Factor SLUG May Drive The Progression Of AKT And Her2/NeuNational Cancer Institute2010–2011
Signal Transduction In OncogenesisNational Cancer Institute1995–2006
Academic Training In Medical OncologyNational Cancer Institute1991–2005
Core--Tissue BankNational Cancer Institute2002
Her-2/Neu Alterations In Breast And Ovarian CancerNational Cancer Institute1995–2002
Phase I Study In Patients With Peritoneal Carcinomatosis Using Sch58500National Center For Research Resources1999–2001
Advances In Human Breast And Prostate CancerNational Cancer Institute2000
Phase I Study In Patients With Peritoneal CarcinomatosisNational Center For Research Resources1998
Clinical Cancer Research DevelopmentNational Cancer Institute1994–1996
Oncogenes In Physiologic And Pathologic StatesNational Cancer Institute1985–1996
Medical OncologyNational Cancer Institute1992–1995
Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
A Program In Medical OncologyNational Cancer Institute1993
Academic Training In HematologyNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1993
UCLA Clinical Cancer Research DevelopmentNational Cancer Institute1992–1993
Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1991–1993
Oncogenes In Physiologic &Pathological StatesNational Cancer Institute1987–1988